{"filings":[{"id":1230890,"accession_number":"0001140361-26-026114","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2026-06-23T21:47:10+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Nuwellis announces 1-for-35 reverse stock split effective June 25, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved 1-for-35 reverse stock split on June 16, 2026, following shareholder authorization obtained on August 4, 2025.","Effective June 25, 2026 at 5:00 PM ET; common stock trades split-adjusted on Nasdaq under symbol NUWE on June 26.","Proportionate adjustments apply to exercise prices and shares under preferred stock, options, RSUs, and warrants.","CUSIP becomes 67113Y801; Equiniti Trust Company serves as exchange agent.","Fractional shares rounded down with cash payment based on last closing price before effectiveness."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1119849,"accession_number":"0001140361-26-025614","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2026-06-17T21:59:23+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Nuwellis appoints Michael McCormick as CEO effective June 30, 2026; Erb remains Chairman","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John Erb resigns as President and CEO effective June 30, 2026; will continue as Chairman of the Board.","Michael McCormick appointed CEO, President, and Board member effective June 30, 2026.","McCormick's base salary set at $431,100 with annual incentive target of 65% of base; one-time equity grant to be determined.","McCormick previously served as consultant (Chief Commercial Officer) since Sep 2025 and as director from June 2023 to Jan 2026.","Board size increased from 5 to 6 members effective June 30, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":956036,"accession_number":"0001140361-26-024740","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2026-06-10T13:09:42+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nuwellis closes $6.0M public offering of shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$6.0M from 1,903,338 common shares and pre-funded warrants with Series C/D warrants.","Public offering price $0.30 per share and accompanying warrants; pre-funded warrants at $0.2999.","As of June 9, 2026, 12,750,321 common shares outstanding (post-exercise of pre-funded warrants).","Series C warrants exercisable at $0.30 for 5 years after stockholder approval and reverse split; Series D warrants include cashless exercise option.","Ladenburg Thalmann acted as sole book-running manager; offering declared effective June 4, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":40206,"accession_number":"0001140361-26-020805","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2026-05-12T20:04:46+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuwellis Q1 net sales $2.4M (+26% YoY); gross margin 70.1%; net loss $4.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net sales $2.4M, up 26% from $1.9M YoY; gross margin 70.1% (improved 14% YoY).","Net loss $4.3M; operating expenses $6.0M (up from $4.1M) due to sales headcount.","Cash $2.2M, no debt as of March 31, 2026.","Acquired Rendiatech (kidney-function monitoring); appointed Carisa Schultz as CFO.","Appointed Martin J. Emerson and David A. McDonald to Board; new patents and TX territory."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93272,"accession_number":"0001140361-26-017826","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nuwellis annual meeting elects two Class I directors, ratifies auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marty J. Emerson elected with 397,057 FOR vs 23,144 withheld; 657,819 broker non-votes.","David A. McDonald elected with 352,646 FOR vs 67,555 withheld; 657,819 broker non-votes.","Ratification of Baker Tilly US as 2026 auditor passed with 1,053,309 FOR, 7,748 AGAINST, 16,963 abstain.","Approximately 43.81% of outstanding shares were represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93271,"accession_number":"0001140361-26-016755","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nuwellis settles E.F. Hutton lawsuit for $204K; mutual release, dismissal with prejudice","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement Agreement executed April 24, 2026; payment of $204,000 within five days.","No admission of liability; mutual release of all claims between Nuwellis and Hutton.","Hutton to file Stipulation of Dismissal with Prejudice within two days of payment.","Lawsuit was previously disclosed on February 26, 2026, alleging breach of engagement letter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93270,"accession_number":"0001140361-26-012781","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K/A","filed_at":"2026-04-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Nuwellis amends 8-K to include former directors' response letters; company disputes statements","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mika Grasso and Katharyn Field resigned from Board effective March 26, 2026.","Supplemental response letters from both former directors filed as Exhibits 17.1 and 17.2.","Company and continuing Board disagree with certain statements in the response letters, standing by initial filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104757,"accession_number":"0001140361-26-011775","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Two Nuwellis directors resign over information-access disagreements; board reduced to five","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mika Grasso and Katharyn Field resigned effective March 26, 2026, citing alleged failures to provide timely information.","Company expressly disagrees with allegations, stating resignation letters contain errors and misleading speculation.","Board size decreased from seven to five members effective March 27, 2026 after resignations.","Company to file any response letters from departing directors within two business days of receipt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104756,"accession_number":"0001140361-26-009745","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2026-03-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nuwellis closes acquisition of Rendiatech, automated kidney monitoring tech","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Closed acquisition of Rendiatech, Inc., an Israeli developer of automated kidney function monitoring technology.","Acquisition previously announced; no financial terms disclosed in this filing.","Technology intended to support clinical decision-making in critically ill patients.","Nuwellis expands product portfolio with monitoring capability."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104755,"accession_number":"0001140361-26-008781","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuwellis Q4 revenue +4% to $2.4M; full year -5%; acquires Rendiatech","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $2.4M (+4% YoY, +9% sequential); gross margin 68.2% vs 58.4% prior year.","Full year 2025 revenue $8.3M (-5% YoY); net loss $17.5M includes $6.4M non-cash warrant expense.","U.S. console sales up 208% YoY in Q4 (8 vs 3 units); Heart Failure +48%, Pediatrics +16%.","Closed $5.0M private placement and warrant inducement in Jan 2026; appointed Carisa Schultz CFO Feb 2, 2026.","Executed definitive stock purchase agreement to acquire Rendiatech; no financial terms disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104754,"accession_number":"0001140361-26-006888","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"Nuwellis appoints two directors; E.F. Hutton files breach-of-contract lawsuit","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Board expanded from 5 to 7; appointed Martin Emerson (Monteris Medical CEO) and David McDonald (Lake Street Vice Chairman) as Class I directors.","Emerson and McDonald are independent, qualify as audit committee financial experts, and will serve on key committees.","On Feb 11, 2026, E.F. Hutton sued Nuwellis for breach of engagement letter as exclusive placement agent for registered offerings, seeking compensatory and punitive damages.","Company intends to vigorously defend; at this preliminary stage, no estimate of possible loss or range can be made."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104753,"accession_number":"0001140361-26-002906","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["1.01","3.02","3.03","5.02","7.01","9.01"],"status":"ready","headline":"Nuwellis raises $5M in private placement and warrant inducement; acquires Rendiatech; appoints new CFO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$5M from private placement (994,537 shares/pre-funded + 1,989,074 warrants) and warrant inducement (623,585 shares exercised, 1,247,170 new warrants).","Agreement to acquire Rendiatech Ltd. for up to $500K cash + 150,000 shares + 30,000 options; Clarity RMS/Prime real-time kidney monitoring tech.","Appointed Carisa Schultz as CFO effective Feb 2, 2026; base salary $265K, bonus up to 40%, standard change-in-control severance.","Company had 1,686,892 shares outstanding as of Jan 29, 2026; warrants add significant potential dilution.","Net proceeds for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104752,"accession_number":"0001140361-26-002241","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Nuwellis appoints two new directors; three resign, board shrinks from 6 to 5","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Three directors (Dave McDonald, Mike McCormick, Maria Costanzo) resigned effective Jan 21, 2026; resignations not due to any disagreement.","Board appointed Katharyn Field and Mika Grasso as Class I directors effective same date; board reduced from 6 to 5 members.","Field is CEO of iSpecimen (ISPC); Grasso is investment manager at private family office; both deemed independent.","New directors must resign if $5M equity investment not made within 30 days of S-1 filing or SEC comment clearance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121031,"accession_number":"0001140361-25-041591","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuwellis Q3 revenue $2.2M, down 6% YoY, up 29% sequentially; operating loss widens to $2.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $2.2M, down 6% YoY but up 29% sequentially; pro-forma revenue grew ~7% YoY excluding one-time items.","Gross margin 65.2% (down from 70% YoY); operating loss $2.7M vs $1.5M last year.","Cash $3.1M at quarter end, debt-free; raised $1.9M via ATM facility.","Launched new 24-hour circuit and dual-lumen catheter; first hospital-based outpatient therapies under new CMS code.","Pediatric Vivian system accelerated with NIH funding; manufacturing transition to KDI Precision initiated."],"consensus_eps_estimate":null,"consensus_eps_actual":-39.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":5846000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121030,"accession_number":"0001140361-25-037713","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2025-10-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Nuwellis CFO Robert Scott resigns; CEO John Erb appointed interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Robert B. Scott resigns; last day on or about Oct 24, 2025; not due to any disagreement.","President & CEO John L. Erb appointed interim CFO effective on the Separation Date.","Erb will receive no additional compensation for the interim CFO role.","Company will commence a formal search for a permanent CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137658,"accession_number":"0001140361-25-036651","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nuwellis announces ULTRA-Peds registry study findings on Aquadex System in pediatric AKI","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["ULTRA-Peds registry is multi-center observational study of real-world Aquadex System use.","Study focused on children with acute kidney injury, fluid overload, or congenital kidney failure.","Findings announced September 30, 2025; no quantitative results or patient numbers disclosed.","Company did not provide financial impact or guidance change in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137657,"accession_number":"0001140361-25-035346","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nuwellis announces US patent issuance for hemolysis sensor technology supporting pediatric device Vivian","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["US Patent No. 12,415,021 issued September 16, 2025, for hemolysis sensors with extracorporeal blood filtration systems.","Patent covers detection and localization of red blood cell destruction in ultrafiltration and CRRT circuits.","Intellectual property supports Nuwellis' pediatric device Vivian and future platform innovation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137656,"accession_number":"0001140361-25-034368","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2025-09-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"NIH awards $3M grant to Nuwellis partner KBT for pediatric CRRT device Vivian","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NIH grant to Koronis Biomedical Technologies supports Nuwellis' pediatric CRRT device Vivian for patients under 20 kg.","Grant is approximately $3 million, multi-year, non-dilutive funding for software and firmware development.","Vivian is a dedicated pediatric CRRT device; grant aims to accelerate development and strengthen Nuwellis portfolio.","Announced on September 9, 2025; Nuwellis ticker NUWE listed on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137655,"accession_number":"0001140361-25-033738","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Nuwellis enters ATM offering to sell up to $4.65M of common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered At The Market Offering Agreement with Ladenburg Thalmann to sell common stock up to $4,650,000.","Sales agent commission of 3.0% of gross proceeds; Ladenburg also gets up to $50,000 expense reimbursement.","Offering is under existing S-3 shelf registration; no obligation to sell any shares.","Prospectus supplement filed September 3, 2025; shares sold at market prices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137654,"accession_number":"0001140361-25-032150","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2025-08-21T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nuwellis gets FDA 510(k) clearance for new catheter size","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA 510(k) clearance received for new size of Nuwellis' Dual Lumen Extended Length Catheter (dELC) on August 21, 2025.","Clearance allows Nuwellis to market the new size catheter in the United States.","No specific dimensions, commercial launch date, or revenue impact disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137653,"accession_number":"0001140361-25-031828","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2025-08-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nuwellis enters non-binding LOI to acquire Rendiatech, an Israeli renal monitoring firm","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Rendiatech specializes in real-time urine flow and acute kidney injury monitoring technologies.","Acquisition intended to expand Nuwellis' platform beyond ultrafiltration into continuous renal health monitoring.","Parties in due diligence; transaction expected to close in Q4 2025, pending board approval and conditions.","No financial terms disclosed in the non-binding letter of intent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137652,"accession_number":"0001140361-25-031093","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuwellis Q2 2025 revenue down 23% YoY to $1.7M; net loss widens to $12.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.7M vs $2.2M in Q2 2024; decline due to sterilization vendor backorder.","Gross margin fell to 55.5% from 67.2%; operating loss $2.9M vs $2.3M.","Net loss attributable to common shareholders $12.6M ($60.99/share) vs $7.7M ($791.82).","Cash $4.5M; debt-free; completed $5.0M gross capital raise in Q2.","Outsourced manufacturing to KDI Precision; added two pediatric centers (47 total); new patent on fluid bag design."],"consensus_eps_estimate":null,"consensus_eps_actual":-100.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":3629000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137651,"accession_number":"0001140361-25-028670","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nuwellis shareholders approve reverse stock split and increase in authorized shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved a reverse stock split of 1:5 to 1:70, with board discretion to implement within 12 months to regain Nasdaq listing compliance.","Authorized common shares increased from 100M to 200M via charter amendment approved by 42,325 for, 15,715 against.","Approved issuance of shares upon exercise of warrants from June 2025 financing (28,004 for, 6,626 against).","Adjournment authority also approved (41,884 for, 14,626 against) if needed to solicit more proxies.","Only 130,154 shares (45.23% of outstanding) were represented at the special meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137650,"accession_number":"0001140361-25-026855","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2025-07-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nuwellis regains compliance with Nasdaq minimum bid price requirement; delisting avoided","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On July 22, 2025, Nasdaq notified Nuwellis that its bid price deficiency was cured and listing continues.","Company had received delisting notice after stock closed below $1.00 for 30 consecutive days.","Reverse stock splits in prior two years made company ineligible for standard compliance period.","Previously scheduled hearing for August 12, 2025 is now moot and cancelled."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137649,"accession_number":"0001140361-25-024517","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2025-07-02T23:59:59+00:00","items":["3.03","5.03","5.02","9.01"],"status":"ready","headline":"Nuwellis appoints John L. Erb as CEO and President, approves 1-for-42 reverse stock split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["John L. Erb appointed President and CEO effective June 27, 2025, with annual base salary of $431,097 and stock option grant of 115,329 shares vesting monthly.","Board approved a 1-for-42 reverse stock split; effective 5:00 p.m. ET on July 3, 2025, with trading on split-adjusted basis from July 7, 2025.","Reverse split proportionally adjusts outstanding stock options, warrants, and preferred shares; new CUSIP 67113Y702.","Mr. Erb continues as Chairman of the Board; employment agreement includes annual bonus target of 65% of base salary.","Reverse split reduces outstanding common shares by a factor of 42, with fractional shares paid in cash based on Nasdaq closing price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155026,"accession_number":"0001140361-25-023368","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nuwellis receives Nasdaq delisting notice for bid price below $1.00; plans reverse split and hearing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq Deficiency Notice on June 18, 2025 for failure to meet $1.00 minimum bid price requirement.","Not eligible for standard compliance period due to prior reverse stock splits totaling at least 250:1 over two years.","Intends to request a hearing and effect a reverse stock split (approved 1:5 to 1:70 at May 20, 2025 meeting) to regain compliance.","No assurance of continued listing; securities remain listed pending final hearing conclusion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155025,"accession_number":"0001140361-25-021870","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["1.01","5.03","3.02","9.01"],"status":"ready","headline":"Nuwellis exchanges CEO's Series F preferred for new Series F-1 with 19.99% conversion cap","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO John L. Erb exchanged 100 shares of Series F Preferred for 100 shares of newly designated Series F-1 Convertible Preferred on June 9, 2025.","Series F-1 includes a beneficial ownership limitation of 19.99% upon conversion, unlike the original Series F.","CEO agreed to convert all Series F-1 shares to common by a deadline tied to the underwriting agreement for S-1 public offering (333-287663).","CEO also agreed to vote in favor of shareholder approval for warrants in that offering as required by Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155024,"accession_number":"0001140361-25-020182","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Nuwellis shareholders authorize 1-for-5 to 1-for-70 reverse stock split to comply with Nasdaq listing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split approved with 1,792,386 votes for, 386,100 against; Board may implement within 12 months.","John L. Erb and Gregory D. Waller elected as Class II directors with ~797K votes each.","Ratification of Baker Tilly US, LLP as auditor for 2025 approved: 2,013,794 votes for.","Adjournment authorization passed with 1,354,662 votes for; broker non-votes of 674,522 on director election."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155023,"accession_number":"0001140361-25-018543","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuwellis Q1 2025 revenue $1.9M (+3% YoY); net loss narrows to $3.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.9M (+3% YoY); consumables utilization +4%; pediatric revenue +38%.","Operating expenses down 31% to $4.1M; operating loss improved to $3.1M from $4.7M.","Net loss $3.0M ($0.69/sh) vs $3.8M ($24.11/sh) in Q1 2024.","CMS reassigned Aquadex to higher outpatient reimbursement (4x to $1,639/day) effective Jan 1, 2025.","Cash $2.6M, debt-free."],"consensus_eps_estimate":-32.5584,"consensus_eps_actual":-0.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":1904000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155022,"accession_number":"0001140361-25-018404","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Nuwellis enters 3-year supply agreement with Kluge Design for Aquadex manufacturing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["KDI exclusively manufactures Aquadex Blood Circuit, dELC Catheter, SmartFlow Console globally; Nuwellis retains IP.","Nuwellis pays start-up costs by Aug 1, 2025; KDI provides 50% credit applied to future Consumable Goods orders.","Pricing based on volume tiers; KDI may increase prices due to material, labor, or tariff changes pass-through.","No minimum purchase; initial term 3 years, auto-renew yearly; exclusivity for KDI as contract manufacturer.","Up to [***] employees transfer to KDI; manufacturing equipment moves to KDI facility in Rogers, MN."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155021,"accession_number":"0001140361-25-012066","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Nuwellis posts updated corporate presentation; no financial details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation posted April 3, 2025 on Nuwellis investor relations website.","Highlights Aquadex SmartFlow as standard of care for fluid management.","No specific financial guidance, revenue, or operational metrics provided.","Filing does not contain material new information beyond the presentation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173537,"accession_number":"0001140361-25-008006","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuwellis Q4 revenue $2.3M (-9% YoY); net loss narrows to $1.5M from $7.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $2.3M, down 9% YoY; consumables utilization +21%, critical care revenue +35%.","Gross margin 58.4% vs 54.4% YoY; includes $150K voluntary recall expense.","Operating loss $2.4M, improved from $3.6M; full-year cost reduction $5.9M (-26%).","Net loss attributable to common $1.5M ($0.44/share) vs $7.9M ($54.48/share) YoY.","Cash $5.1M, no debt; CMS payment for Aquadex increased 4x to $1,639 effective Jan 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173536,"accession_number":"0001140361-25-005675","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Nuwellis CEO Nestor Jaramillo Jr. retires; Chairman John Erb named interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nestor Jaramillo Jr. retired as President, CEO, and director effective Feb 18, 2025; retirement was not due to any dispute.","Jaramillo will receive 6 months base salary, a $47,723 bonus payment, COBRA premiums through Aug 2025, and accelerated stock options.","Board appointed Chairman John L. Erb as Interim President and CEO; he will receive an annual salary of $300,000 and remain Chairman.","Board reduced size from seven to six members; company will retain an executive search firm for a permanent CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190522,"accession_number":"0001140361-24-049903","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nuwellis regains Nasdaq compliance with bid price and equity listing rules","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq confirmation of compliance with minimum bid price (Rule 5550(a)(2)) and stockholders' equity (Rule 5550(b)(1)).","Company raised $5.1M in gross proceeds from warrant exercises and a November warrant inducement transaction.","Implemented a 1:35 reverse stock split on June 26, 2024 to help regain bid price compliance.","Subject to mandatory panel monitor for one year from December 17, 2024; no further cure period if non-compliant.","CEO Nestor Jaramillo cited balance sheet improvements including reduced liabilities and reclassified warrant liabilities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190521,"accession_number":"0001140361-24-049660","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Nuwellis voluntarily recalls AquaFlexFlow UF 500 Plus blood circuits over mismatch alarms","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Recall of specific lots due to 'Ultrafiltrate Weight Mismatch' alarms; may cause excess fluid removal leading to acute volume depletion.","Five reported incidences of product failures; three caused patient dehydration requiring fluid administration.","Recall conducted with FDA knowledge; FDA has not yet classified recall class.","Affected product: AquaFlexFlow UF 500 Plus blood circuit used with Aquadex Smartflow or FlexFlow systems."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190520,"accession_number":"0001140361-24-046009","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuwellis Q3 revenue $2.4M, net income $2.4M; CMS reimbursement up 297%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.4M, down 2% YoY; pediatrics revenue grew 28% YoY.","Gross margin 70% vs 57.3% YoY; operating expenses down 30% YoY.","Net income attributable to common $2.4M ($1.74/share) vs loss $3.4M; includes $3.9M warrant liability benefit.","CMS increased Aquadex facility fee reimbursement 297% to $1,639/day, effective Jan 1, 2025.","Cash $1.9M, no debt; $5.1M gross proceeds from November warrant exercise."],"consensus_eps_estimate":null,"consensus_eps_actual":-14.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":6418000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190519,"accession_number":"0001140361-24-045441","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["1.01","3.02","3.03","8.01","9.01"],"status":"ready","headline":"Nuwellis raises $5.1M via warrant inducement; issues new warrants for 3.7M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Total gross proceeds of $5.1M, including $3.8M from immediate exercise of 1.8M existing warrants at $2.10 and $1.3M from recent exercises at original terms.","Issued Series I and II warrants to purchase up to 3.7M shares at $1.94, exercisable starting 6 months from issuance, with 5-year and 2-year terms respectively.","Pro forma shares outstanding ~4.1M after exercise, up from 2.2M prior; company to file resale registration statement within 15 days.","Ladenburg Thalmann served as exclusive inducement agent, receiving 8% cash fee and Placement Agent Warrants for 55K shares at $3.465.","New warrants are unregistered and private, with anti-dilution and variable transaction restrictions until February 26, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190518,"accession_number":"0001140361-24-045016","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuwellis reports preliminary Q3 revenue ~$2.4M, gross margin 70%, cash $1.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of approximately $2.4 million; pediatric category grew 28% YoY.","Gross margin improved to 70% from 57.3% YoY; operating costs fell ~30%.","Cash used in ops ~$2.5M; cash and equivalents ~$1.9M at quarter end.","SeaStar settlement: $900K aggregate due by Dec 31, 2024; ~$500K received.","Full Q3 results and earnings call scheduled for November 11, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-14.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":6418000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190517,"accession_number":"0001140361-24-044033","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2024-10-23T23:59:59+00:00","items":["1.02","9.01"],"status":"ready","headline":"Nuwellis terminates distribution deal with SeaStar Medical, receives $900k settlement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SeaStar pays Nuwellis $900k in three installments: $500k (less offsets) by Oct 22, $250k by Nov 30, $150k by Dec 31, 2024.","Distribution and supply agreements for QUELIMMUNE terminated effective Oct 20, 2024; Nuwellis to return remaining inventory.","Settlement resolves SeaStar's May 2024 breach notice (disputed by Nuwellis) with no admission of liability.","Parties mutually release all claims related to the agreements and agree to non-disparagement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207023,"accession_number":"0001140361-24-038578","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2024-08-26T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Nuwellis prices $916,000 registered direct offering with warrants at $1.72 strike","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$916k from sale of 496,901 shares at $1.845/share and warrants for 496,901 shares.","Warrants exercisable immediately at $1.72/share, expiring 5 years from registration effectiveness.","Offering closed Aug 26, 2024; net proceeds for working capital and general corporate purposes.","Ladenburg Thalmann acted as exclusive placement agent; cash fee of 8% of gross proceeds.","Company also issued placement agent warrants to purchase 14,501 shares at $3.04425, expiring Aug 23, 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207022,"accession_number":"0001140361-24-038108","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2024-08-22T23:59:59+00:00","items":["1.02","9.01"],"status":"ready","headline":"Nuwellis and DaVita mutually terminate Supply and Collaboration Agreement effective Aug 21, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Supply and Collaboration Agreement with DaVita terminated by mutual agreement effective August 21, 2024.","Common Stock Purchase Warrant never vested because vesting milestones were not attained.","Registration rights under the agreement never became effective due to lack of Ultrafiltration Services Approval.","All rented and unused products under the Supply Agreement are to be returned to Nuwellis."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207021,"accession_number":"0001140361-24-036995","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Nuwellis Q2 revenue up 6% to $2.2M; gross margin expands to 67.2%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.2M (+6% YoY); Critical Care revenue up 28%, Heart Failure consumables utilization up 35%.","Gross margin 67.2% vs 55.3% prior year; total operating expenses down 38% to $3.8M.","Net loss $7.7M vs $4.8M; basic EPS loss $18.85 vs $127.65 (improved due to share count changes).","Cash and equivalents $1.0M; no debt; closed registered direct offering for $2.0M gross proceeds on July 25.","Expanded Aquadex to pediatric patients in Florida hospital network; signed purchase agreement with 50-hospital Texas network."],"consensus_eps_estimate":null,"consensus_eps_actual":-40.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":4051000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207020,"accession_number":"0001140361-24-036718","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nuwellis granted continued Nasdaq listing subject to Q3 2024 10-Q evidencing equity compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq panel granted continued listing on August 8, 2024, following July 23 hearing.","Condition requires filing of Q3 2024 10-Q showing compliance with Stockholder's Equity Requirement.","Company regained Minimum Bid Price compliance on July 18, 2024.","No assurance that company can meet all listing criteria within granted period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207019,"accession_number":"0001140361-24-034104","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2024-07-25T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Nuwellis prices $2M registered direct offering of 469,340 shares at $4.24 plus warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$2.0M; net proceeds ~$1.6M after fees.","Share price $4.24; accompanying warrants exercisable at $3.99 for up to 938,680 shares.","Closing expected July 25, 2024; Roth Capital Partners acting as exclusive placement agent.","Proceeds to be used for working capital and general corporate purposes.","Warrants issued in private placement under Section 4(a)(2) and Regulation D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207018,"accession_number":"0001140361-24-033362","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2024-07-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Nuwellis announces first commercial sale of QUELIMMUNE therapy for pediatric AKI/sepsis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First commercial sale of QUELIMMUNE to Cincinnati Children's Hospital for pediatric AKI/sepsis patients.","QUELIMMUNE (Selective Cytopheretic Device) developed by SeaStar Medical; early data show 77% survival rate.","Sale under exclusive US distribution agreement with SeaStar Medical (ICU); FDA Humanitarian Device Exemption.","Dr. Stuart Goldstein, principal investigator, will integrate QUELIMMUNE as standard of care at Cincinnati Children's.","CEO Nestor Jaramillo: milestone advances Nuwellis' pediatric business development strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207017,"accession_number":"0001140361-24-033343","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2024-07-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nuwellis adds risk factor on off-label Aquadex use in neonates under 20 kg","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Aquadex System cleared only for patients ≥20 kg, but is being modified for neonates/kidney failure infants.","FDA may view company communications as off-label promotion, risking untitled letters, fines, or criminal penalties.","Off-label promotion could trigger False Claims Act lawsuits, exclusion from Medicare/Medicaid, and corporate integrity agreements.","Updated corporate presentation posted on IR website; no specific financial or strategic changes disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207015,"accession_number":"0001140361-24-033392","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K/A","filed_at":"2024-07-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Nuwellis adds off-label use risk factor and updates investor presentation","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed 8-K/A to replace corporate presentation; updated version posted to investor website.","Added risk factor detailing potential penalties from off-label promotion of Aquadex system, including use in neonates.","Risk factor warns of FDA enforcement, False Claims Act suits, and exclusion from Medicare/Medicaid for off-label marketing.","No changes to financial statements or other disclosures from prior 10-Q; no new business results provided.","Company states its off-label communications are compliant but acknowledges regulatory authorities may disagree."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207016,"accession_number":"0001140361-24-032403","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2024-07-03T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Nuwellis terminates ATM equity offering agreement with Ladenburg Thalmann effective July 9, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Termination notice delivered to Ladenburg Thalmann & Co. Inc. on July 1, 2024; effective July 9, 2024.","ATM Agreement dated March 3, 2023 permitted periodic issuance and sale of common stock shares.","No additional shares of common stock will be issued or sold under the terminated ATM Agreement.","Company had been selling shares under Instruction I.B.6 of Form S-3 limitations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224319,"accession_number":"0001140361-24-031389","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"Nuwellis (NUWE) to effect 1-for-35 reverse stock split on June 27, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nuwellis (NUWE) approved 1-for-35 reverse stock split effective 5:00 pm ET June 27, 2024.","Trading begins split-adjusted June 28 on Nasdaq under same symbol; new CUSIP 67113Y603.","Authorized shares unchanged at 100M; outstanding shares reduced proportionally; fractional shares redeemed.","Reverse split authorized by stockholders on June 6; Board set ratio on June 18."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224318,"accession_number":"0001140361-24-029567","cik":1506492,"company_name":"Nuwellis, Inc.","ticker":"NUWE","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["3.01","5.07"],"status":"ready","headline":"Nuwellis receives Nasdaq delisting notice for bid price non-compliance; shareholders approve reverse stock split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq notified Nuwellis on June 5, 2024 of delisting due to continued non-compliance with $1.00 minimum bid price requirement.","Company will request a hearing before the Nasdaq Hearings Panel to stay delisting; no assurance of continued listing.","Stockholders approved a reverse stock split at a ratio of 1-for-5 to 1-for-70 to help regain compliance.","Reverse split approval received 1,676,112 votes for, 1,095,593 against, 4,694 abstain.","Company also faces non-compliance with $2.5M minimum stockholders' equity requirement reported previously."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1983488.6094760457,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2024-06-10T23:59:59+00:00|224318"}